NKNesrine Kallel

Nesrine Kallel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nesrine Kallel has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • EGFR mutation spectrum and clinical correlations in Tunisian Non-Small cell lung cancer patients

    by Rania Abdelmaksoud-Dammak, Nihel Ammous-Boukhris, Slim Charfi, Nesrine Kallel, Rim Khemakhem, Ameni Feki, Tahya Sellami Boudawara, Ilhem Yangui, Afef Khanfir, Raja Mokdad Gargouri

  • Sleep habits and quality among war and conflict-affected Palestinian adults in the Gaza strip

    by Sameh Msaad, Nouha Ketata, Sabrine Fidha, Rahma Gargouri, Hazem Al Talaa, Israa Wadhane, Nesrine Kallel, Najla Bahloul, Walid Feki, Jihène Jedidi, et al.


  • Open Access

    Predominance of the Rare EGFR Mutation p.L861Q in Tunisian Patients with Non-Small Cell Lung Carcinoma

    by Rania Abdelmaksoud-Dammak, Nihel Ammous-Boukhris, Amèna Saadallah-Kallel, Slim Charfi, Souhir Khemiri, Rim Khemakhem, Nesrin Kallel, Wala Ben Kridis-Rejeb, Tahya Sallemi-Boudawara, Afef Khanfir, et al.

    Objectives: Several new cancer therapies targeting signaling pathways involved in the growth and progression of cancer cells were developed as personalized medicine. Our study aimed to identify epidermal growth factor receptor (EGFR) mutations for TKI treatment in non-small-cell lung cancer (NSCLC) Tunisian patients. Methods: Analysis of the TKI sensitivity mutations in exons 18 to 21 of the EGFR gene and exon 15 of the B-raf gene was performed in 79 formalin fixed-paraffin embedded (FFPE) NSCLC samples using pyrosequencing. Results: EGFR mutations were detected in 34 cases among 79 (43%), with the predominance of the L861Q in exon 21 found in 35.3% of the cases (12 out of 34). Deletions in exon 19 were found in 8 cases (23.5%), and only one young male patient had the T790M mutation. Three patients harbored composite EGFR mutations (p.E746_A750del/p.L861R, p.E746_S752>V/p.S768I, and p.G719A/p.L861Q). Furthermore, the EGFR mutated status was significantly more frequent in female patients (p = 0.019), in non-smoker patients (p = 0.008), and in patients with metastasis (p = 0.044). Moreover, the B-raf V600E was identified in 5 EGFR negative patients among 39 analyzed samples (13.15%). Conclusion: The p.L861Q localized in exon 21 of the EGFR gene was the most common mutation identified in our patients (35.3%), whereas the “classic” EGFR mutations such as Del19 and p.L858R were found in 23.5% and 11.7% of the cases, respectively. Interestingly, most of p.L861X mutation-carrying patients showed good response to TKI treatment. Altogether, our findings suggest a particular distribution of the EGFR-TKIs sensitivity mutations in Tunisian NSCLC patients.


  • Open Access

    Coronavirus disease 19 (COVID‐19) and Cerebral venous sinus thrombosis (CVST): A case series and review of the literature

    by Nesrine Kallel, Amal Saidani, Amina Kotti, Nedia Moussa, Sabrine Maddeh, Rahma Gargouri, Sameh Msaad, Walid Feki

    A large proportion of patients with coronavirus disease 19 (COVID‐19) suffer from excessive coagulation activation and coagulopathy which predisposes them to a wide spectrum of thrombotic events including in situ pulmonary thrombosis, deep‐vein thrombosis, and associated pulmonary embolism, as well as arterial thrombotic events. Cerebral venous sinus thrombosis (CVST) have also been reported but in a very small number of cases. This report aims to increase awareness about CVST as a potential neurological thromboembolic complication in patients with coronavirus disease. We report three COVID‐19 patients presenting with CVTS. We also review all previously described cases and present an overview of their demographic, clinical, and diagnostic data. We describe three patients with concomitant coronavirus disease and CVST among 1000 hospitalized COVID‐19 patients (2 males, 1female, and mean age of 37 years). One patient was previously healthy, while the two others had a history of chronic anemia and ulcerative colitis, respectively. CVST symptoms including seizure in two patients and headache in one patient occurred day to weeks after the onset of COVID‐19 symptoms. Three months of anticoagulant therapy was given for all three patients with favorable outcomes. No neurological sequelae and no recurrence occurred within 6 months after hospital discharge. Our search identified 33 cases of COVID‐19 complicated by CVST. The mean age was 45.3 years, there was a slight male predominance (60%), and more than half of cases were diagnosed in previously healthy individuals. All cases of CVT were clinically symptomatic and were observed in patients with a different spectrum of coronavirus disease severity. Headache was the most common complaint, reported by just less than half of patients. There was a high mortality rate (30.3%). CVT is a very rare, but potentially life‐threatening complication in patients with COVID‐19. It's mainly reported in relatively young individuals with no or little comorbid disease and can occur even in patients who do not display severe respiratory symptoms. Atypical clinical presentations may pose a challenge to the early diagnosis and treatment. High suspicion is necessary as early diagnosis and prompt treatment with anticoagulation in all patients with COVID‐19 and CVT could contain the mortality rate and improve neurological outcomes in these patients.


  • Open Access

    Leser‐Trélat syndrome secondary to non‐small‐cell lung carcinoma

    by Rim Khemakhem, Nesrine Kallel, Rahma Jarraya, Ilhem Yangui, Samy Kammoun

    The syndrome of Leser‐Trélat (LT) is a rare paraneoplastic syndrome. However, patients presenting with the sign of Leser‐Trélat should be considered to harbor an occult malignancy or a progressive tumor disease until “proven” otherwise. Herein, we present two cases of non‐small‐cell lung carcinoma associated with LT syndrome.


  • Open Access

    First Reported Cases of COVID-19-Associated Mucormycosis in Tunisia

    by Ichrak Bougharriou, Rim Khemakhem, Nesrine Kallel, Anis Bafoun, Feten Mahmoudi, Samy Kammoun

    COVID-19 infection is associated with several complications such as mucormycosis. We report, to the best of our knowledge, the first published cases of mucormycosis associated with severe COVID-19 infection in Tunisia. The first case was a diabetic, 68-year-old man, who presented a rhino-orbito-cerebral mucromycosis. The second case was a 37-year-old woman with a chronic renal failure hemodialysis stage and liver disease and who presented a rhino-sinuso-orbital mucormycosis. The diagnosis of mucormycosis was retained in both cases seven days after COVID-19 infection. Antifungal treatment was prescriped. Surgical treatment was not possible. Both cases died. We should think about mucormycosis in patients with COVID-19 infection and emergency medical and surgical treatment must be started to reduce mortality.

  • Open Access

    Primary thoracic synovial sarcomas: A case report

    by Nesrine Kallel, Darine Sakka, Asma Zaafouri, Rim Khemakhem, Ilhem Yangui, Sameh Msaad

    Primary pulmonary synovial sarcoma (SS) is a rare neoplasm. Its clinicoradiologic attributes are not yet well defined. We report the observation of a patient followed for primary pulmonary synovial sarcoma. We report the radio‐clinical features of this rare tumor.

  • Open Access

    Characteristics of Obese Patients with Acute Hypercapnia Respiratory Failure Admitted in the Department of Pneumology: An Observational Study of a North African Population

    by Sameh Msaad, Rahma Gargouri, Amina Kotti, Nesrine Kallel, Amel Saidane, Yassine Jmel, Wajdi Ketata, Nadia Moussa, Amine Bahloul, Samy Kammoun, et al.

    Background. Acute hypercapnic respiratory failure (AHRF) is a common life-threatening event in patients with obesity hypoventilation syndrome (OHS). Objectives. To study the clinical pattern, noninvasive ventilatory support, as well as the short- and long-term outcomes of patients with OHS admitted in a ward because of AHRF. Methods. We conducted a retrospective cohort study including all adults with OHS , admitted in a 90-bed-ward for AHRF. Results. A total of 44 patients were included. Fifteen (34.1%) and 29 (65.9%) patients were diagnosed with malignant OHS (mOHS) and nonmalignant OHS (non-mOHS), respectively, while 36 (81.8%) had coexisting obstructive sleep apnea hypopnea syndrome (OSAHS). Patients with mOHS had a significantly higher rate of heart failure (100% vs. 31%; ), chronic renal insufficiency (CRI) (73.3% vs. 41.4%; ), and dyslipidemia (66.7% vs. 34.5%; ) than those with non-mOHS. The mean forced vital capacity (FVC) in our patients was of of the predicted value, lower than what is usually reported in stable patients with OHS. At hospital admission, more than two-thirds ( , 77.3%) were misdiagnosed as having asthma exacerbation ( , 4.9.1%), chronic obstructive pulmonary disease (COPD) exacerbation ( , 27.3%) and/or heart failure ( , 65.9%). Acute pulmonary oedema (ACPE) ( , 36.4%) and acute viral bronchitis ( , 27.3%) were the main identified causal factors, while no cause could be determined in 5 (11.4%) patients. Noninvasive positive pressure ventilation (NIPPV) using bilevel positive airway pressure (BIPAP) was very highly effective to treat AHRF, with only 2.27% of patients failing the modality. Median overall duration of ventilation was 9 hours per day (1.3–20) and was significantly longer in patients with mOHS than in those with non-mOHS (10 [6–18] vs. 8 [1.3–20], respectively; <use...


  • Open Access

    Primary thoracic synovial sarcomas: a case report

    by Nesrine Kallel, Darine Sakka, Asma Zaafouri, Rim Khemekhem, Ilhem Yangui, Sameh Msaad

    Primary pulmonary synovial sarcoma (SS) is a rare neoplasm. Its clinicoradiologic attributes are not yet well defined. We report the observation of a patient followed for primary pulmonary synovial sarcoma. we report the radio-clinical features of this rare tumor.

  • Bacteriological and therapeutic features of lung abscess

    by Nessrine Kallel, Rim Khemakhem, Khouloud Abdelmouleh, Nedia Moussa, Ilhem Yangui, Samy Kammoun

    Background: Primary lung abscess is necrotic cavitary lesion of the lung parenchyma. It is usually caused by anaerobic bacteria or mixed flora. The aim of this study was to describe the epidemiological, clinical, bacteriological and therapeutic features of lung abscess. Methods: This is a retrospective, descriptive study, conducted over a period of 3 years, including patients hospitalized for lung abscess. Results: Our study included 24 patients which mostly were men. The average age was 46.8 years. Sixty percent were smokers. The main patient illness histories were COPD (25%), diabetes (15%), cerebral stroke (5%), epilepsy (5%) and cerebral palsy(5%). The clinical symptomatology was dominated by fever, chest pain and deterioration of the general state. The most common location was the right upper lobe (35%). The bacteriological examination of sputum was negative in 21 patients and positive for pneumococcus (1 case), staphylococcus (1 case) and E. coli (1 case). One case of pseudomonas aeruginosa was isolated by bacteriological examination of the percutaneous drainage fluid. Nine patients (37.5%) were treated with amoxicillin-clavulanic acid and fluoroquinolone and 33.5% of patients received triple therapy included C3G with metronidazeole and fluoroquinolone. The mean duration of treatment was 3.8 weeks. Percutaneous drainage was indicated in 3 patients. Complete resolution of radiological abnormalities was 30 days. Conclusion: The identification of the responsible bacteria in lung abcess remains difficult. Management is based mainly on antibiotics wich is often probabilistic, in some cases associated with physiotherapy, percutaneous scan-guided drainage or rarely surgery.